RIPE-KG · Version 1.1.0 · Resource
ripekg:work/10.1016%2Fj.antiviral.2020.104787
https://w3id.org/ripe/ripe-kg/work/10.1016%2Fj.antiviral.2020.104787
| Subject | Predicate | Object |
|---|---|---|
ripekg:work/10.1016%2Fj.antiviral.2020.104787The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro |
prism:doi |
10.1016/j.antiviral.2020.104787 |
ripekg:work/10.1016%2Fj.antiviral.2020.104787The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro |
dcterms:title |
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro |
ripekg:work/10.1016%2Fj.antiviral.2020.104787The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro |
rdf:type |
node1 |
ripekg:work/10.1016%2Fj.antiviral.2020.104787The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro |
rdf:type |
http://purl.org/spar/fabio/Work |
ripekg:work/10.1016%2Fj.antiviral.2020.104787The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro |
rdf:type |
rdfs:Resource |
ripekg:work/10.1016%2Fj.antiviral.2020.104787The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro |
rdf:type |
owl:Thing |
ripekg:work/10.1016%2Fj.antiviral.2020.104787The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro |
rdf:type |
prov:Entity |
ripekg:work/10.1016%2Fj.antiviral.2020.104787The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro |
rdf:type |
ripe:WorkWork |
ripekg:work/10.1016%2Fj.antiviral.2020.104787The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro |
owl:sameAs |
https://semopenalex.org/work/W3014962324 |
ripekg:work/10.3390%2Fv13060989RETRACTED: Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon |
http://purl.org/spar/cito/cites |
ripekg:work/10.1016%2Fj.antiviral.2020.104787The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro |